{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:23:29Z","timestamp":1768980209488,"version":"3.49.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10,1]]},"DOI":"10.1093\/cvr\/cvr168","type":"journal-article","created":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T04:28:22Z","timestamp":1308198502000},"page":"159-168","source":"Crossref","is-referenced-by-count":30,"title":["A role for coagulation factor Xa in experimental pulmonary arterial hypertension"],"prefix":"10.1093","volume":"92","author":[{"given":"Martina","family":"Delbeck","sequence":"first","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin F.","family":"Nickel","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Perzborn","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Ellinghaus","sequence":"additional","affiliation":[{"name":"Target Discovery, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Strassburger","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raimund","family":"Kast","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Laux","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sch\u00e4fer","sequence":"additional","affiliation":[{"name":"Cardiology Research, Bayer HealthCare, Wuppertal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralph T.","family":"Schermuly","sequence":"additional","affiliation":[{"name":"Max-Planck-Institute for Heart and Lung Research, Giessen\/Bad Nauheim, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"von Degenfeld","sequence":"additional","affiliation":[{"name":"Common Mechanism Research, Bayer HealthCare, Wuppertal, Germany"},{"name":"Institute for Research in Operative Medicine, University of Witten\/Herdecke, Cologne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2011,6,15]]},"reference":[{"key":"key\n\t\t\t\t20180726065946_CVR168C1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2008.10.002","article-title":"Therapeutic targets in pulmonary arterial hypertension","volume":"121","author":"Rhodes","year":"2009","journal-title":"Pharmacol Ther"},{"key":"key\n\t\t\t\t20180726065946_CVR168C2","first-page":"531","article-title":"Pulmonary arterial hypertension: an overview of current pharmacologic treatment","volume":"72","author":"Reinhart","year":"2008","journal-title":"Conn Med"},{"key":"key\n\t\t\t\t20180726065946_CVR168C3","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1378\/chest.06-2674","article-title":"Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines","volume":"131","author":"Badesch","year":"2007","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180726065946_CVR168C4","doi-asserted-by":"crossref","first-page":"35S","DOI":"10.1378\/chest.126.1_suppl.35S","article-title":"Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines","volume":"126","author":"Badesch","year":"2004","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180726065946_CVR168C5","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1164\/ajrccm\/139.3.763","article-title":"Effect of heparin and warfarin on chronic hypoxic pulmonary hypertension and vascular remodeling in the guinea pig","volume":"139","author":"Hassoun","year":"1989","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180726065946_CVR168C6","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1164\/ajrccm\/148.4_Pt_1.1043","article-title":"Chronic hypoxic pulmonary hypertension. Is thrombin involved?","volume":"148","author":"Hampl","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180726065946_CVR168C7","first-page":"747","article-title":"Impairment of hypoxic pulmonary artery remodeling by heparin in mice","volume":"128","author":"Hales","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180726065946_CVR168C8","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/BF01910461","article-title":"Hypotensive effect of heparin on experimental chronic pulmonary hypertension in rats","volume":"80","author":"Kentera","year":"1985","journal-title":"Basic Res Cardiol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C9","first-page":"113","article-title":"The effect of heparin on the haemodynamic and structural response in the rat to acute and chronic hypoxia","volume":"70","author":"Hu","year":"1989","journal-title":"Br J Exp Pathol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C10","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1164\/ajrccm\/145.1.193","article-title":"Partial reversal of hypoxic pulmonary hypertension by heparin","volume":"145","author":"Hassoun","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"key\n\t\t\t\t20180726065946_CVR168C11","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180726065946_CVR168C12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180726065946_CVR168C13","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180726065946_CVR168C14","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180726065946_CVR168C15","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1111\/j.1476-5381.1994.tb17126.x","article-title":"Antithrombotic actions of argatroban in rat models of venous, \u2018mixed\u2019 and arterial thrombosis, and its effects on the tail transection bleeding time","volume":"113","author":"Berry","year":"1994","journal-title":"Br J Pharmacol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C16","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-2999(98)00101-0","article-title":"Relationship between the antithrombotic effect of YM-75466, a novel factor Xa inhibitor, and coagulation parameters in rats","volume":"347","author":"Sato","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C17","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1538-7836.2005.01166.x","article-title":"In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939\u2013an oral, direct Factor Xa inhibitor","volume":"3","author":"Perzborn","year":"2005","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20180726065946_CVR168C18","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"key\n\t\t\t\t20180726065946_CVR168C19","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1161\/CIRCULATIONAHA.108.779751","article-title":"Combined tyrosine and serine\/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling","volume":"118","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180726065946_CVR168C20","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/00498250500250493","article-title":"Pharmacokinetics of BAY 59-7939\u2014an oral, direct Factor Xa inhibitor\u2014in rats and dogs","volume":"35","author":"Weinz","year":"2005","journal-title":"Xenobiotica"},{"key":"key\n\t\t\t\t20180726065946_CVR168C21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/0753-3322(90)90135-V","article-title":"Pharmacokinetics and tissue distribution of 99mTc-labelled enoxaparin in the rat: evaluation of dosimetry parameters","volume":"44","author":"Colas Linhart","year":"1990","journal-title":"Biomed Pharmacother"},{"key":"key\n\t\t\t\t20180726065946_CVR168C22","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1161\/CIRCULATIONAHA.106.676809","article-title":"Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy","volume":"115","author":"Schermuly","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180726065946_CVR168C23","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1161\/CIRCULATIONAHA.107.728634","article-title":"Letter by Klein regarding article, \u2018Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study","volume":"117","author":"Klein","year":"2008","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180726065946_CVR168C24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1183\/09031936.00002007","article-title":"Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3\/4 inhibition","volume":"31","author":"Dony","year":"2008","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180726065946_CVR168C25","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","article-title":"Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction","volume":"162","author":"Chomczynski","year":"1987","journal-title":"Anal Biochem"},{"key":"key\n\t\t\t\t20180726065946_CVR168C26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/0041-008X(89)90012-4","article-title":"Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats","volume":"99","author":"White","year":"1989","journal-title":"Toxicol Appl Pharmacol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C27","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1152\/jappl.1983.55.5.1445","article-title":"Changes in arteriole in acute and chronic hypoxic pulmonary hypertension and recovery in rat","volume":"55","author":"Sobin","year":"1983","journal-title":"J Appl Physiol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C28","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0041-008X(88)90006-3","article-title":"Pulmonary platelet sequestration is increased following monocrotaline pyrrole treatment of rats","volume":"96","author":"White","year":"1988","journal-title":"Toxicol Appl Pharmacol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1152\/jappl.1987.62.2.816","article-title":"Neither anticoagulant nor nonanticoagulant heparin affects monocrotaline lung injury","volume":"62","author":"Fasules","year":"1987","journal-title":"J Appl Physiol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C30","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1378\/chest.06-0941","article-title":"Low-molecular-weight heparin inhibits hypoxic pulmonary hypertension and vascular remodeling in guinea pigs","volume":"132","author":"Al Ansari","year":"2007","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180726065946_CVR168C31","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1161\/01.CIR.80.5.1198","article-title":"Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry","volume":"80","author":"Pietra","year":"1989","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180726065946_CVR168C32","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1378\/chest.122.5.1674","article-title":"Significance of a plasma D-dimer test in patients with primary pulmonary hypertension","volume":"122","author":"Shitrit","year":"2002","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180726065946_CVR168C33","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1016\/j.thromres.2010.08.020","article-title":"Calibrated automated thrombography demonstrates hypercoagulability in patients with idiopathic pulmonary arterial hypertension","volume":"126","author":"Tournier","year":"2010","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20180726065946_CVR168C34","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1183\/09031936.06.00015206","article-title":"Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review","volume":"28","author":"Johnson","year":"2006","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180726065946_CVR168C35","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1056\/NEJM199207093270203","article-title":"The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension","volume":"327","author":"Rich","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180726065946_CVR168C36","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1161\/01.CIR.82.3.841","article-title":"Fibrinopeptide A levels indicative of pulmonary vascular thrombosis in patients with primary pulmonary hypertension","volume":"82","author":"Eisenberg","year":"1990","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180726065946_CVR168C37","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1164\/ajrccm.150.4.7921465","article-title":"Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension","volume":"150","author":"Huber","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20180726065946_CVR168C38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1055\/s-0037-1617105","article-title":"Anticoagulation in pulmonary arterial hypertension","volume":"28","author":"Grunig","year":"2008","journal-title":"Hamostaseologie"},{"key":"key\n\t\t\t\t20180726065946_CVR168C39","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1183\/09031936.98.12061446","article-title":"Plasma coagulation profiles in patients with severe primary pulmonary hypertension","volume":"12","author":"Hoeper","year":"1998","journal-title":"Eur Respir J"},{"key":"key\n\t\t\t\t20180726065946_CVR168C40","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00210-006-0087-9","article-title":"How valid are animal models to evaluate treatments for pulmonary hypertension?","volume":"373","author":"Campian","year":"2006","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key\n\t\t\t\t20180726065946_CVR168C41","doi-asserted-by":"crossref","first-page":"392","DOI":"10.3181\/00379727-124-31748","article-title":"Renal and pulmonary alterations induced in rats by a single injection of monocrotaline","volume":"124","author":"Hayashi","year":"1967","journal-title":"Proc Soc Exp Biol Med"}],"container-title":["Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cardiovascres\/article-pdf\/92\/1\/159\/25229446\/cvr168.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,11]],"date-time":"2019-06-11T20:13:09Z","timestamp":1560283989000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cardiovascres\/article\/92\/1\/159\/540361"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2011,6,15]]},"published-print":{"date-parts":[[2011,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cvr\/cvr168","relation":{},"ISSN":["1755-3245","0008-6363"],"issn-type":[{"value":"1755-3245","type":"electronic"},{"value":"0008-6363","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,10,1]]},"published":{"date-parts":[[2011,6,15]]}}}